Siltuximab

• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting
  2023-506235-15-00 Phase III 12 countries Amgen Inc.
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 Phase III 9 countries Amgen Inc.
• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended
  2024-520050-38-00 Phase III 13 countries Amgen Inc.
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended
  2024-516051-40-00 Phase II 6 countries Amgen Inc.
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended
  2024-513968-25-00 Phase III 11 countries Amgen Inc.
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended
  2023-505989-29-00 Phase III 16 countries Amgen Inc.
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended
  2022-502669-14-00 Phase III 15 countries Amgen Inc.
• A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC). Ended
  2024-511837-37-00 Phase II 9 countries Amgen Inc.
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended
  2023-504830-23-00 Phase III 13 countries Genmab A/S
• First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer Ended
  2023-504012-16-00 Phase I (FiH) 2 countries Takeda Development Center Americas Inc.

Showing 1–10 of 10 trials